Main Page  /  For Investors  /  Return on Investment and Exit Strategies
  
1-609-841-1201          

Return on Investment and Exit Strategies

Русский
English

Return on Investment and Exit Strategies

Return on investment will be obtained by implementation of the three complementary financial strategies:
 
a)  The most typical financial strategy of a biotech company is to conduct preclinical and clinical development (including Phase I and II clinical trials) and then license the product to a large pharmaceutical company (see Market Comparables).
 
b) The first complimentary strategy is to simultaneously conduct clinical development as well as product development for the treatment of companion animals (cats and dogs). Companion animals are now living longer and, as a result, reach old age and succumb to age-related diseases of which cancer is one of the most dangerous.  There is a huge unmet medical need for efficacious cancer treatments for cats and dogs; and, we plan to satisfy this need with our anti-cancer genetic vaccine Elenagen.
 
Clinical trials for veterinary drugs are less expensive than trials for human drugs. They can be conducted faster; and, veterinary anti-cancer drugs may reach the market as soon as 1.5 to 2 years following inception of the animal studies.  Moreover, the revenue stream produced by veterinary drug sales may serve as a way to generate an intermediate return on investment.
 
We have already achieved initial positive results in companion animals. And, an international comparative medicine multi-center testing in cats and dogs is currently underway in the US, Europe, Israel, Russia and Ukraine.
 
c)  The second complimentary strategy is to develop Elenagen and to bring it to market in a country where the whole regulatory process takes less time than in an FDA- or EMA-regulated environment (e.g., Russia). This would be accomplished with:
 
1)  The revenue generating return on investment, and
2)  Knowledge gained from the development/clinical trials and regulatory submission processes in the USA and European Union of prior human anti-cancer treatments. 
  
 
Разработка SEO-Online Шаблоны Amiro
Работает на Amiro CMS - Free